Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia.

Authors

Annie Jin, Temple University
Bobak T. Pousti, Temple University
Kevin T. Savage, Drexel University College of Medicine
Nicholas K. Mollanazar, University of Pennsylvania
Jason B. Lee, Thomas Jefferson UniversityFollow
Sylvia Hsu, Temple University

Document Type

Article

Publication Date

9-1-2019

Comments

This article has been peer reviewed. It is the author’s final published version in JAAD Case Reports, 
Volume 5, Issue 9, September 2019, Pages 815-817.

The published version is available at https://doi.org/10.1016/j.jdcr.2019.07.026. Copyright © Jin et al.

Abstract

Leukemia cutis (LC) and eosinophilic dermatosis of hematologic malignancy (EDHM) are rare cutaneous manifestations of hematologic malignancies. Various therapeutic options have been reported, with largely underwhelming responses. We present a patient with chronic lymphocytic leukemia (CLL) with concomitant LC and EDHM who was treated with dupilumab.

Recommended Citation

Jin, Annie; Pousti, Bobak T.; Savage, Kevin T.; Mollanazar, Nicholas K.; Lee, Jason B.; and Hsu, Sylvia, "Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia." (2019). Department of Dermatology and Cutaneous Biology Faculty Papers. Paper 114.
https://jdc.jefferson.edu/dcbfp/114

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

31508473

Language

English